These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. Kananen K; Volin L; Laitinen K; Alfthan H; Ruutu T; Välimäki MJ J Clin Endocrinol Metab; 2005 Jul; 90(7):3877-85. PubMed ID: 15797959 [TBL] [Abstract][Full Text] [Related]
3. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473 [TBL] [Abstract][Full Text] [Related]
4. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189 [TBL] [Abstract][Full Text] [Related]
5. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000 [TBL] [Abstract][Full Text] [Related]
6. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Krieg MA; Seydoux C; Sandini L; Goy JJ; Berguer DG; Thiébaud D; Burckhardt P Osteoporos Int; 2001; 12(2):112-6. PubMed ID: 11303710 [TBL] [Abstract][Full Text] [Related]
7. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Yao S; McCarthy PL; Dunford LM; Roy DM; Brown K; Paplham P; Syta M; Lamonica D; Smiley S; Battiwalla M; Padmanabhan S; Hahn T Bone Marrow Transplant; 2008 Feb; 41(4):393-8. PubMed ID: 17994116 [TBL] [Abstract][Full Text] [Related]
8. Low-dose pamidronate for treatment of early bone loss following kidney transplantation: a randomized controlled trial. Shahidi S; Ashrafi F; Mohammadi M; Moeinzadeh F; Atapour A Iran J Kidney Dis; 2015 Jan; 9(1):50-5. PubMed ID: 25599737 [TBL] [Abstract][Full Text] [Related]
9. Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss. Buchs N; Helg C; Collao C; Chapuis B; Slosman D; Bonjour JP; Rizzoli R Osteoporos Int; 2001; 12(10):880-6. PubMed ID: 11716193 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. Ebeling PR; Thomas DM; Erbas B; Hopper JL; Szer J; Grigg AP J Bone Miner Res; 1999 Mar; 14(3):342-50. PubMed ID: 10027899 [TBL] [Abstract][Full Text] [Related]
11. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Bianda T; Linka A; Junga G; Brunner H; Steinert H; Kiowski W; Schmid C Calcif Tissue Int; 2000 Aug; 67(2):116-21. PubMed ID: 10920215 [TBL] [Abstract][Full Text] [Related]
12. Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Fan SL; Kumar S; Cunningham J Kidney Int; 2003 Jun; 63(6):2275-9. PubMed ID: 12753318 [TBL] [Abstract][Full Text] [Related]
13. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. Tauchmanovà L; Ricci P; Serio B; Lombardi G; Colao A; Rotoli B; Selleri C J Clin Endocrinol Metab; 2005 Feb; 90(2):627-34. PubMed ID: 15546907 [TBL] [Abstract][Full Text] [Related]
14. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. Shane E; Rodino MA; McMahon DJ; Addesso V; Staron RB; Seibel MJ; Mancini D; Michler RE; Lo SH J Heart Lung Transplant; 1998 Nov; 17(11):1089-96. PubMed ID: 9855448 [TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864 [TBL] [Abstract][Full Text] [Related]
16. Pamidronate therapy as prevention of bone loss following renal transplantation. Fan SL; Almond MK; Ball E; Evans K; Cunningham J Kidney Int; 2000 Feb; 57(2):684-90. PubMed ID: 10652047 [TBL] [Abstract][Full Text] [Related]
17. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Boutsen Y; Jamart J; Esselinckx W; Stoffel M; Devogelaer JP Calcif Tissue Int; 1997 Oct; 61(4):266-71. PubMed ID: 9312195 [TBL] [Abstract][Full Text] [Related]
18. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. Trombetti A; Gerbase MW; Spiliopoulos A; Slosman DO; Nicod LP; Rizzoli R J Heart Lung Transplant; 2000 Aug; 19(8):736-43. PubMed ID: 10967266 [TBL] [Abstract][Full Text] [Related]
19. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Walsh SB; Altmann P; Pattison J; Wilkie M; Yaqoob MM; Dudley C; Cockwell P; Sweny P; Banks LM; Hall-Craggs M; Noonan K; Andrews C; Cunningham J Am J Kidney Dis; 2009 May; 53(5):856-65. PubMed ID: 19393473 [TBL] [Abstract][Full Text] [Related]
20. Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis. Orr-Walker B; Wattie DJ; Evans MC; Reid IR Clin Endocrinol (Oxf); 1997 Jan; 46(1):87-92. PubMed ID: 9059563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]